Genprex, Inc.
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
GNPX | US
Overview
Corporate Details
- ISIN(s):
- US3724461047
- LEI:
- Country:
- United States of America
- Address:
- 1601 TRINITY STREET, BLDG. B, 78712 AUSTIN
- Website:
- https://www.genprex.com/
Description
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapeutic options for large patient populations. Its oncology pipeline includes clinical-stage programs for lung cancer, such as the Acclaim-3 trial in small cell lung cancer (SCLC) and other programs for non-small cell lung cancer (NSCLC). In addition to its cancer programs, Genprex is developing gene therapies for diabetes. The company utilizes a proprietary, non-viral nanoparticle delivery system to systemically deliver therapeutic genes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 13:10 |
8-K - Genprex, Inc. (0001595248) (Filer)
|
English | 66.7 KB |
Automate Your Workflow. Get a real-time feed of all Genprex, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genprex, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genprex, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
